[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hypertriglyceridemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":74,"states":75},"Hypertriglyceridemia",10,9,[8,16,22,28,35,41,48,54,61,67],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07604974","A Study to Assess the Safety, Tolerability and Efficacy of ION775",[12],"Phase 2","RECRUITING","2026-08-26T02:15:34.659160Z","2026-05-29T15:36:40.222891Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07269210","A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia",[12],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.713828Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07199309","A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol",[12],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:29.509197Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT06822790","Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia",[32],"Phase 3","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:28.338990Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06880770","Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis",[32],"2026-08-26T02:18:32.765187Z","2026-04-29T02:57:57.151721Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT07491172","A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias",[45],"Phase 1","2026-08-26T02:18:15.214990Z","2026-05-05T02:43:29.073051Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07063056","Curcumin & Astaxanthin for Lowering Triglyceride Readings and Inflammation",[],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:28.518411Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT06494488","Differential Thrombogenesis by EPA and DHA Mediated by HDL",[58],"Early Phase 1","2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.355676Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06451770","Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia",[45],"2026-08-26T02:17:47.813245Z","2026-07-19T19:36:05.132526Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT07715890","Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia",[],"NOT_YET_RECRUITING","2026-08-26T02:18:03.638950Z","2026-07-24T01:27:14.914840Z",[],[76,80,83,87,90,93,97,100,103,106,109],{"state":77,"count":78,"slug":79},"California",5,"california",{"state":81,"count":78,"slug":82},"Florida","florida",{"state":84,"count":85,"slug":86},"New York",4,"new-york",{"state":88,"count":85,"slug":89},"Ohio","ohio",{"state":91,"count":85,"slug":92},"Texas","texas",{"state":94,"count":95,"slug":96},"Illinois",3,"illinois",{"state":98,"count":95,"slug":99},"Indiana","indiana",{"state":101,"count":95,"slug":102},"Maryland","maryland",{"state":104,"count":95,"slug":105},"Michigan","michigan",{"state":107,"count":95,"slug":108},"North Carolina","north-carolina",{"state":110,"count":95,"slug":111},"Washington","washington"]